Abstract:CAR T cell therapy is a promising approach to improve outcomes and decrease toxicities for patients with cancer. While extraordinary success has been achieved using CAR T cells to treat patients with CD19-positive malignancies, multiple obstacles have so far limited the benefit of CAR T cell therapy for patients with solid tumors. Novel manufacturing and engineering approaches show great promise to enhance CAR T cell function against solid tumors. However, similar to single agent chemotherapy approaches, CAR T cell monotherapy may be unable to achieve high cure rates for patients with difficult to treat solid tumors. Thus, combinatorial drug plus CAR T cell approaches are likely required to achieve widespread clinical success.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to find drugs that can enhance the function of CAR T cells through high - throughput screening methods, especially those that can increase the expression of B7 - H3 antigen on the surface of solid tumor cells. Specifically, the researchers developed a high - content screening technique based on confocal microscopy to evaluate whether 1,114 drugs approved by the US Food and Drug Administration (FDA) can increase the expression of B7 - H3 antigen on the surface of osteosarcoma cells (LM7 cell line). The study found that one of the drugs named ingenol - 3 - angelate (I3A) can significantly increase the expression of B7 - H3, thereby enhancing the function of B7 - H3 - CAR T cells, including cytokine production and cytotoxic effects. The key points of the paper include: 1. **Background**: CAR T - cell therapy has achieved remarkable success in the treatment of certain hematological tumors, but still faces many challenges in the treatment of solid tumors, such as the lack of ideal target antigens, tumor heterogeneity, obstacles to the migration of T cells to tumor sites, and immunosuppressive factors in the tumor microenvironment. 2. **Methods**: A high - content screening technique was used to evaluate the effect of 1,114 FDA - approved drugs on the expression of B7 - H3 on the surface of osteosarcoma cells. 3. **Results**: 55 drugs that can increase the expression of B7 - H3 were found, among which I3A has the most significant effect and can increase the expression of B7 - H3 by up to 100%. Further research shows that I3A increases the mRNA, total protein and cell - surface expression of B7 - H3 by activating protein kinase C alpha (PKCα). 4. **Conclusion**: This study shows that high - content and high - throughput screening techniques can be used to identify drugs that enhance CAR T - cell activity, which provides a new approach for the development of rational drug - CAR T - cell combination treatment strategies. Through this method, the researchers not only provide new ideas for enhancing the effectiveness of CAR T - cell therapy against solid tumors, but also provide theoretical basis and technical support for the design of future clinical trials.

A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Tuning the performance of CAR T cell immunotherapies

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Bright future or blind alley? CAR-T cell therapy for solid tumors

Current Clinical Application of the CAR-T Cell Therapy

Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Optimising CAR T therapy for the treatment of solid tumors

Metabolic challenges and interventions in CAR T cell therapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Engineering Enhanced CAR T-cells for Improved Cancer Therapy.

Target Selection of CAR T Cell Therapy in Accordance with the TME for Solid Tumors.